Contents
Contents
Bundled discounts change Medicaid Best Price when a customer earns a qualifying concession through linked purchases or purchasing commitments. In the Protonix case, the government alleged that Wyeth tied discounts on its oral and intravenous drugs together to win hospital business, then left those discounts out of Medicaid’s price reports. The hospital got a deal. Taxpayers allegedly lost the Medicaid rebate that should have followed it. If you worked on the hospital offer or the government pricing calculation, you may recognize how the same arrangement could look different inside two departments.
Medicaid Best Price is the lowest qualifying price a manufacturer makes available to specified purchasers during the rebate period. Those purchasers include wholesalers, retailers, providers and health maintenance organizations. The price includes qualifying cash discounts, volume discounts, rebates and free goods tied to a purchase requirement.
The net terms of the sale are what count. A price concession paid after the original purchase can matter just as much as a discount printed on the invoice. A purchasing condition can connect drugs that arrive in different packages. The commercial agreement tells you what the customer had to do to earn the price.
Manufacturers report average manufacturer price and Best Price to the Centers for Medicare & Medicaid Services. The agency uses the reported prices to calculate Medicaid rebates. For brand drugs subject to the Best Price calculation, the basic rebate compares the difference between average manufacturer price and Best Price with a minimum percentage rebate, using whichever is greater. For most brand drugs, that minimum rose from 15.1 percent to 23.1 percent in 2010, after the Protonix conduct. An additional rebate addresses price increases above inflation.
A qualifying lower Best Price can therefore increase the rebate owed on Medicaid purchases. The government has a financial interest in a discount negotiated with a private customer, even though it never signed that customer’s contract. That connection is what made the hospital deals in Protonix a Medicaid issue.
Wyeth and Pfizer agreed to a $784.6 million settlement in April 2016 over allegations that Wyeth underpaid Medicaid rebates. In its announcement of the settlement, the Justice Department described deep discounts to thousands of hospitals on Protonix Oral and Protonix IV, both proton pump inhibitor drugs.
Public Citizen’s 2018 report, Twenty-seven years of pharmaceutical industry criminal and civil penalties: 1991 through 2017, identified the Wyeth rebate resolution as the largest settlement announced in its 2016 to 2017 study period. The report classified the allegations as overcharging a government health program.
According to the government, Wyeth bundled the discounts to induce hospitals to use the oral drug despite competing oral products that were competitively priced and considered at least as safe and effective. The alleged offer tied the oral and intravenous prices together to give hospitals a reason to choose Protonix Oral.
The government alleged that Wyeth hid those bundled discounts from Medicaid and avoided hundreds of millions of dollars in rebates from 2001 to 2006. The hospital’s purchasing arrangement supplied the concession. The manufacturer’s reporting determined whether Medicaid received the benefit through its rebate.
The government alleged that the hospital discount bought access to prescriptions after discharge, when Medicaid and other healthcare payers would bear the cost:
Wyeth wanted to control the hospital market because patients discharged from the hospital on Protonix Oral were likely to stay on the drug for long periods of time, during which payers, including Medicaid, would pay nearly full price for the drug.
Justice Department, account of the government’s Protonix allegations, April 27, 2016
The manufacturer allegedly wanted the hospital’s purchasing decision to carry forward into outpatient prescriptions, while keeping the discount behind. Medicaid’s rebate was supposed to bring the qualifying concession into the government’s price too.
Best Price allocation for the Protonix oral and IV bundle turns on how a linked discount affects the price assigned to each drug. Separate product names and invoices do not describe the whole bargain when the discount depends on buying across products.
The Centers for Medicare & Medicaid Services’ December 2020 explanation of bundled sales describes the allocation rule in commercial terms. A bundle can turn on purchases of the same drug, different drugs or another product. It can also turn on a performance requirement, such as market share or placement on a formulary, the list of drugs a payer covers. Physical packaging does not control the answer.
The rule allocates the discount proportionally to the total dollar value of the units of all drugs or products sold under the arrangement. When several drugs are discounted, the combined value of the discounts is allocated across the drugs or products in the bundle. The scope of the deal determines which sales belong in that allocation.
For someone in contracting, the revealing language is the condition attached to the offer. For someone in government pricing, what matters is where that concession lands in the calculation. The condition that earns the discount and the calculation that reports it describe different parts of the same transaction.
That later rule explains allocation. The historical Protonix allegation was that the linked hospital discounts disappeared from Medicaid reporting.
The manufacturer supplies the pricing information, while the state supplies Medicaid utilization. Manufacturers report quarterly average manufacturer price and Best Price within 30 days after the quarter closes. The agency’s calculation translates the manufacturer-reported price into a rebate per unit, which applies to the state’s reported units. A missing concession can therefore affect what the manufacturer owes beyond the hospital sale that generated it.
Price reports require certification by a senior officer or an authorized delegate. The underlying pricing information is confidential, subject to statutory exceptions. A public list price, before discounts, cannot show how a particular hospital agreement entered the company’s Best Price calculation.
The reporting obligation also follows later price changes. The rule requires a manufacturer to adjust Best Price when cumulative discounts, rebates or other arrangements change the available price, unless the concession is excluded. The initial invoice can precede the final concession. The pricing calculation has to follow the terms the customer ultimately receives.
This is why a government pricing employee’s knowledge can matter alongside a hospital contracting employee’s. One may understand the condition that made the deal valuable. The other may know how the company treated it when reporting the price. We connect those accounts to the transaction and the rebate obligation.
The purchase channel determines which prices enter Best Price. Qualifying 340B prices and prices negotiated by Medicare Part D plans are among the excluded transactions. A hospital’s 340B purchase and its commercial bundled offer therefore raise different pricing questions.
Nominal pricing has its own boundary: the exclusion requires a price below 10 percent of average manufacturer price and an eligible recipient. In a separate case, the government alleged that Merck improperly called hospital discounts nominal and left them out of its reported prices. A label on the deal can hide the same rebate problem as an omitted bundle.
The Centers for Medicare & Medicaid Services’ December 2020 final rule allowed qualifying value-based purchasing arrangements, which link price or payment to therapeutic or clinical value, to receive bundled-sale treatment. It also established a multiple-Best-Price option. The agency’s subsequent reporting clarification identifies July 1, 2022 as that option’s start, for qualifying arrangements offered to all states.
For a qualifying value-based bundle, discounts on purchases outside the arrangement stay outside its allocation. Those other concessions still count toward the actual price the customer receives. The deal’s boundaries determine the allocation. The earlier Protonix case concerned allegedly omitted hospital discounts.
Aventis agreed to a $95.5 million civil settlement in May 2009 over allegedly omitted private-label discounts, a smaller settlement than the later Protonix rebate payment. The Justice Department’s account concerned Azmacort, Nasacort and Nasacort AQ sold under private-label agreements with Kaiser Permanente. The government alleged that repackaging the drugs under another label concealed the prices that should have entered Medicaid’s Best Price calculation.
That arrangement used a different route to the same reporting problem. A customer received a favorable price, and the government alleged that Medicaid did not receive the rebate benefit. In Aventis, the question followed a private label. In Protonix, it followed the connection between discounts on different products. Both cases put the terms available to the customer beside the price reported to the government.
Pfizer’s December 2012 Protonix settlement was a separate $55 million civil resolution concerning alleged promotion and the sale of misbranded Protonix. That smaller settlement addressed how the product was promoted and sold. The later rebate case addressed hospital discounts and the rebates owed to a public health care program.
For a bundled-discount allegation, the useful evidence connects the customer agreement, the purchases and concessions under it, the manufacturer’s pricing calculation, and the price reported for Medicaid rebates. The company’s knowledge of that connection matters too.
We work through that connection with you, including who understood the arrangement and how it reached the people responsible for reporting. Your role may give you a view of the offer, the calculation or both.
Two whistleblowers brought the allegations resolved by the Wyeth settlement. The agreement provided a combined whistleblower share of about $98 million from the federal and state recovery. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
If you know a hospital discount was missing from Medicaid pricing, speak with our whistleblower experts about the agreement and the reporting behind it. We work beside you to build your strongest Medicaid rebate whistleblower case, from the commercial deal through the government’s lost rebates, and bring in pharmaceutical pricing whistleblower lawyers who understand bundled discounts. Your knowledge of what the customer received can be the starting point for recovering what Medicaid was owed.